Home>>Signaling Pathways>> Cardiovascular>> Atherosclerosis>>PAz-PC

PAz-PC

(Synonyms: Azelaoyl PC, 1Palmitoyl2Azelaoyl PC) 目录号 : GC44573

A major oxLDL form

PAz-PC Chemical Structure

Cas No.:117746-89-1

规格 价格 库存 购买数量
1mg
¥565.00
现货
5mg
¥2,552.00
现货
10mg
¥4,523.00
现货
25mg
¥9,901.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.

Chemical Properties

Cas No. 117746-89-1 SDF
别名 Azelaoyl PC, 1Palmitoyl2Azelaoyl PC
Canonical SMILES O=P([O-])(OCC[N+](C)(C)C)OC[C@H](OC(CCCCCCCC(O)=O)=O)COC(CCCCCCCCCCCCCCC)=O
分子式 C33H64NO10P 分子量 665.8
溶解度 DMF: 1 mg/ml,DMSO: 5 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 5 mg/ml 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.502 mL 7.5098 mL 15.0195 mL
5 mM 0.3004 mL 1.502 mL 3.0039 mL
10 mM 0.1502 mL 0.751 mL 1.502 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

The activation of liver X receptors inhibits toll-like receptor-9-induced foam cell formation

J Cell Physiol 2010 Apr;223(1):158-67.PMID:20049870DOI:10.1002/jcp.22022.

Toll-like receptors (TLRs) are related to foam cell formation (FCF), key event in the establishment/progression of atherosclerosis. The activation of TLR2 and TLR4 can increase FCF. The aim of this study was to evaluate the role of TLR9 in FCF. Murine macrophages were treated with CpG-ODN, TLR9 agonist, and oxidized particles of LDL (PAz-PC) and FCF was analyzed by means of Oil Red O staining. The administration of CpG-ODN plus PAz-PC onto macrophages increased the amount of lipid droplets, correlated to increased levels of tumor necrosis factor (TNF)-alpha, IFNbeta, and IP-10. The underlying mechanism by which TLR9 ligation influenced PAz-PC in the FCF was NF-kappaB- and IRF7-dependent, as observed by higher levels of phosphorylated IkappaBalpha, increased nuclear translocation of the p65 subunit, lower levels of the total IKKalpha protein and higher release of interferon-dependent cytokines, such as IP-10. Liver X receptors (LXRs) regulate lipid cellular transport and negatively modulate TLR-dependent signaling pathways. Indeed, the addition of GW3965, synthetic LXRs agonist, significantly reduced FCF after CpG-ODN plus PAz-PC stimulation. In this condition, we observed decreased levels of the nuclear translocation of the p65 subunit, related to the higher presence of LXRalpha into the nucleus. TNF-alpha, IP-10, and IFNbeta levels were reduced by the administration of GW3965 following CpG-ODN and PAz-PC treatment. In conclusion, the activation of TLR9 facilitates the formation of foam cells in an NF-kappaB- and IRF7-dependent manner, countered by the activation of LXRs. This study further support LXRs as potential anti-atherosclerotic target.